CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Compugen Ltd (CGEN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock has no strong technical or proprietary trading signals, weak financial performance, and limited positive catalysts. While the company's immuno-oncology pipeline has potential, the current financials and technical indicators do not support immediate investment.
The MACD is below 0 and negatively contracting, indicating a bearish momentum. RSI is neutral at 60.38, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 1.789), which could limit further upside in the short term.
The company has a promising immuno-oncology pipeline, including Phase 3 development programs with AstraZeneca. Analysts have a Buy rating with a $4 price target, citing potential peak royalties of over $200M.
Weak financial performance in Q3 2025 with significant YoY declines in revenue (-88.96%), net income (-646.94%), and EPS (-800%). Gross margin also dropped significantly (-83.87%). Technical indicators suggest limited short-term upside, and the stock has a 60% chance of declining in the next day, week, and month.
In Q3 2025, revenue dropped to $1.891M (-88.96% YoY), net income fell to -$6.979M (-646.94% YoY), and EPS dropped to -0.07 (-800% YoY). Gross margin decreased to 12.74% (-83.87% YoY), indicating significant financial struggles.
H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing the company's immuno-oncology pipeline and potential peak royalties of over $200M. However, no recent upgrades or changes in ratings were noted.
